Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

Inclusion Criteria: * Must have relapsed or refractory multiple myeloma (RRMM) after having received prior lines of anti-myeloma treatments. * Measurable disease as defined by one of the following: abnormal serum or M-protein levels; abnormal serum free light chain (FLC) assay; ≥ 30% clonal plasma cells in the bone marrow aspirate or biopsy sample * Evidence of cell membrane CD38 expression as determined by immunohistochemistry (IHC) analysis ofbone marrow biopsy or extramedullary plasmacytoma * Pulse oximetry ≥ 92% on room air * Have a life expectancy ≥ 12 weeks * Be willing and able to comply with the study schedule and all study requirements * Willing to follow contraception guidelines Exclusion Criteria: * Previous treatment with any systemic therapy for multiple myeloma within 14 days prior to start of study dose * Treatment with any cellular therapy within 8 weeks prior to start of study dose * Have any unresolved toxicity ≥ Grade 2 from previous anticancer therapies * A history of brain metastasis or spinal cord compression * Has an ECOG performance status (PS) ≥ 3 * Has received allogeneic hematopoietic stem cell transplantation (HSCT) within 6 months, has active graft-versus-host disease (GvHD) following transplant, or is currently receiving immunosuppressive therapy following transplant * Has any clinically significant low baseline lab results for hemoglobin, platelet counts, and neutrophil counts at screening unless resulting from underlying RRMM * Has any clinically significant elevated baseline lab results for serum creatinine, AST or β2 microglobulin * Abnormal INR or aPTT, unless on a stable dose of an anticoagulant * Has known HIV or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C * Is currently pregnant or breast feeding or planning on either during the study. * Has an active bacterial, viral, or fungal infection * Has active plasma cell leukemia * Has extramedullary plasmacytoma(s) * Has any significant medical condition, abnormality, or psychiatric illness that would prevent study participation * Has left ventricular ejection fraction (LVEF) \< 40% * Has second primary malignancies (SPMs) in addition to multiple myeloma if the SPM has required therapy within the last 3 years or is not in complete remission * Has any additional clinical history of the CNS or cardiovascular disease that would place the patient at an unacceptable risk if the patient participates in the study